Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B

Basit Öğe Kaydı
dc.authoridAlan, Saadet/0000-0003-2329-151X
dc.authoridyalniz, mehmet/0000-0001-7776-4154
dc.authorwosidAlan, Saadet/ABH-4282-2020
dc.authorwosidyalniz, mehmet/G-6767-2015
dc.contributor.authorAtes, Fehmi
dc.contributor.authorYalniz, Mehmet
dc.contributor.authorAlan, Saadet
dc.date.accessioned2024-08-04T20:59:00Z
dc.date.available2024-08-04T20:59:00Z
dc.date.issued2011
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAIM: To evaluate the impact of liver steatosis upon response to given therapy in chronic hepatitis B (CHB) patients. METHODS: 84 consecutive CHB patients treated with 48-wk PEGylated interferon (PEG-IFN) therapy were enrolled. Baseline characteristics and sustained viral response (SVR) to PEG-IFN therapy were evaluated. RESULTS: Mean body mass index (BMI) was 27.36 +/- 4.4 kg/m(2). Six (7.1%) had hypertension and three (3.5%) had diabetes mellitus. Steatosis was present in 22.6% (19/84) of liver biopsy samples. Age, BMI, and triglyceride levels of the patients with hepatic steatosis were significantly higher than those without hepatic steatosis (P < 0.05). SVR to PEG-IFN therapy was 21.4% (18/84). Sixteen of these 18 CHB patients with SVR (88.9%) did not have any histopathologically determined steatosis. On the other hand, only two of the 19 CHB patients with hepatic steatosis had SVR (10.5%). Although the SVR rate observed in patients without steatosis (16/65, 24.6%) was higher compared to those with steatosis (2/19, 10.5%), the difference was not statistically significant (P > 0.05). CONCLUSION: Occurrence of hepatic steatosis is significantly high in CHB patients and this association leads to a trend of decreased, but statistically insignificant, SVR rates to PEG-IFN treatment. (C) 2011 Baishideng. All rights reserved.en_US
dc.identifier.doi10.3748/wjg.v17.i40.4517
dc.identifier.endpage4522en_US
dc.identifier.issn1007-9327
dc.identifier.issn2219-2840
dc.identifier.issue40en_US
dc.identifier.pmid22110283en_US
dc.identifier.startpage4517en_US
dc.identifier.urihttps://doi.org/10.3748/wjg.v17.i40.4517
dc.identifier.urihttps://hdl.handle.net/11616/103359
dc.identifier.volume17en_US
dc.identifier.wosWOS:000297467700010en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBaishideng Publishing Group Incen_US
dc.relation.ispartofWorld Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic hepatitis Ben_US
dc.subjectHepatic steatosisen_US
dc.subjectPEGylated interferon therapyen_US
dc.titleImpact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis Ben_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu